Abstract:BackgroundPositiveallosteric modulators of GABAA receptors transduce a host ofbeneficial effects but can have motor and sedative liabilities. A benzodiazepine, HZ‐166, had previously been characterized as an alpha 2,3‐selective GABAA receptor modulator with anticonvulsant, anxiolytic, and anti‐nociceptive properties but reduced motor effects. However, the ester moiety in HZ‐166 quickly metabolizes to the carboxylic acid leading to variable exposures of ester in plasma and brain. Moreover, the acid of HZ‐166 possesses significant invitro activity and may well contribute to efficacy seen in in vivo models. We have identified five membered ringheterocycles (oxazoles, dioxazoles) as competent ester replacements which lend themselves to comparable in vitro potency, reduced metabolic complications, consequently leading to an overall increase in unbound central concentration and thus increased efficacy in animal models of pain and epilepsy.MethodsPlasmaand brain exposures of compounds were assessed after i.p. dosing. Compounds were evaluated for efficacy inseveral rodent seizure‐induction models. We also evaluated the anti‐nociceptive effects of one compound (KRM‐II‐81)in rats exposed to chronic pain induced by spinal nerve ligation (SNL) (L5/6)by the Von Frey test. Finally,assessment of motor impairment was evaluated on the inverted screen test.ResultsKRM‐II‐81which utilizes a bioisosteric oxazole as a five membered ring heterocycle replacementof the ester in HZ‐166 did not negatively affect selectivity for α 3(0.97 μM) over α 1 (> 20 μM). However, KRM‐II‐81 demonstrated enhancedbrain exposure versus HZ‐166 after systemic administration. Accordingly, unbound mouse brain exposure exhibited by KRM‐II‐81 after 1 hr (10 mg/kg, i.p.) was 978 nM. In contrast, HZ‐166 possessed >100 folddecrease in mouse unbound brain concentration (6.4 nM) when dosed under the same conditions. Increased central exposure translated to increased efficacy without induction of motor side effects. KRM‐II‐81 (30 mg/kg, i.p.) was fully protective against pentylenetetrazole (PTZ)‐induced clonic convulsions in rats (ED50 = 10.2 mg/kg), whereas HZ‐166 was only partially effective. Further, whereas HZ‐166 (up to 60 mg/kg, i.p.) was ineffective in increasing the dose of i.v.‐infused PTZ required for convulsions, KRM‐II‐81 was efficacious at a dose as low as 10 mg/kg. HZ‐166 was also not active against electroshock‐induced convulsions in mice while KRM‐II‐81 showed efficacy at 30 mg/kg. KRM‐II‐81 also increased pain thresholds by ~2.5 times, an effect equivalent to gabapentin without observable changes in sedation or motor impairment. Brains from SNL rats exhibited decreases in K+‐evoked glutamate release.ConclusionsSubstitution of an oxazole bioisostere for the ester in HZZ‐166 did not affect selectivity α subtype selectivity but significantly increased mouse brain exposure after systemic dosing. Increased brain exposure translated to increased potency and efficacy in rodent seizure‐induction models as well as efficacy against nociceptive challenge in a rodent chronic pain model. In addition, motor side‐effects were not exacerbated by KRM‐II‐81. Thus, KRM‐II‐81 represents a significant advance in the pharmacology of the GABAa receptor.

Zolpidem Activation of Alpha 1-Containing GABAA Receptors Selectively Inhibits High Frequency Action Potential Firing of Cortical Neurons

Lateral Habenula Glutamatergic Neurons Modulate Isoflurane Anesthesia in Mice.

The GABAA receptor modulator zolpidem augments hippocampal-prefrontal coupling during non-REM sleep

Pharmaco-EEG analysis of ligands varying in selectivity for α1 subunit-containing GABAA receptors during the active phase in rats

Benzodiazepine actions mediated by specific γ-aminobutyric acidA receptor subtypes

Zolpidem, a clinical hypnotic that affects electronic transfer, alters synaptic activity through potential GABA receptors in the nervous system without significant free radical generation

Structure-Activity Relationship of Neuroactive Steroids, Midazolam, and Perampanel Toward Mitigating Tetramine-Triggered Activity in Murine Hippocampal Neuronal Networks

A Novel, A-2, 3-Selective Gaba(A) Receptor Modulator with Improved Central Penetrability and Associated Antiepileptic and Anti-Pain Efficacy

Virus-mediated swapping of zolpidem-insensitive with zolpidem-sensitive GABA(A) receptors in cortical pyramidal cells

Evaluation of the sedative-motor effects of novel GABAkine imidazodiazepines using quantitative observation techniques in rhesus monkeys

GABAergic modulation in central sensitization in humans: a randomized placebo-controlled pharmacokinetic-pharmacodynamic study comparing clobazam with clonazepam in healthy volunteers

Prolonged Zaleplon Treatment Increases the Expression of Proteins Involved in GABAergic and Glutamatergic Signaling in the Rat Hippocampus

Modulation of spinal GABAergic analgesia by inhibition of chloride extrusion capacity in mice

Propofol downregulates the activity of glutamatergic neurons in the basal forebrain via affecting intrinsic membrane properties and postsynaptic GABAARs

Heteromeric GABAA receptor structures in positively-modulated active states

Effects of midazolam on high‐frequency oscillations in amygdala and hippocampus of epilepsy patients

3 β-Methyl-Neurosteroid Analogs Are Preferential Positive Allosteric Modulators and Direct Activators of Extrasynaptic δ-Subunit γ-Aminobutyric Acid Type A Receptors in the Hippocampus Dentate Gyrus Subfield

Light-Activated Agonist-Potentiator of GABA A Receptors for Reversible Neuroinhibition in Wildtype Mice

Extrasynaptic GABAA receptors in central medial thalamus mediate anesthesia in rats

Selective Enhancement of the Interneuron Network and Gamma-Band Power via GluN2C/GluN2D NMDA Receptor Potentiation

Downstream Allosteric Modulation of NMDA Receptors by 3-Benzazepine Derivatives